• Join
  • Login
  • Contact

Search abstracts

Effectiveness and safety of mepolizumab in the treatment of severe eosinophilic asthma

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-092
  • By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
  • Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, santander, Spain)
    Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
    Mrs Julia Sanchez Gundin, Hospital Pharmacist
    Mrs Victor Fernandez Martinez, Hospital Pharmacist
    Ms Marina Barbara Ramis Barcelo, Hospital Pharmacist
    Mrs Marta Valero Dominguez, Hospital Pharmacist
  • Abstract:

    Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity. IL-5 is the major cytokine responsible for the growth and
    differentiation, recruitment, activation and survival of eosinophils.

    To analyse the effectiveness of mepolizumab in patients..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses